Endo International Confirms $10.6 Billion Bid for Salix

March 12, 2015

Willkie Client Centerview Partners serves as financial advisor to Salix Pharmaceuticals, a leader in the gastrointestinal market 

On March 11, Endo International plc presented the Board of Directors of Salix Pharmaceuticals, Ltd. with a bid to combine the two companies in a cash-and-stock transaction valued at $10.6 billion. Willkie represents Centerview Partners, which serves as a financial advisor to Salix, a leader in the gastrointestinal market. Willkie also represented Centerview Partners in the agreement by Valeant Pharmaceuticals to acquire Salix for $10.4 billion ($14.5 billion, including debt), announced in February. Click here to read Willkie’s announcement.

Based in Raleigh, NC, Salix licenses, develops, and markets products to treat gastroenterology disorders.

The Willkie deal team was led by partner Steven Seidman and included partners Laura Delanoy, Sean Ewen, Tariq Mundiya and Antonio Yanez, and associates Laura Acker and Margaret McSpadden.